Rilvegostomig
- Generic Name
- Rilvegostomig
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Phase 3
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1220
- Registration Number
- NCT06921785
- Locations
- 🇻🇳
Research Site, Ho Chi Minh City, Vietnam
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 830
- Registration Number
- NCT06868277
- Locations
- 🇬🇧
Research Site, Blackpool, United Kingdom
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Phase 3
Recruiting
- Conditions
- HER2-positive Gastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 840
- Registration Number
- NCT06764875
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 880
- Registration Number
- NCT06692738
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
Phase 2
Not yet recruiting
- Conditions
- Stomach Neoplasms
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Jeeyun Lee
- Target Recruit Count
- 50
- Registration Number
- NCT06630130
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Phase 3
Recruiting
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 878
- Registration Number
- NCT06627647
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
Phase 3
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT06564844
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Phase 3
Recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- Diagnostic Test: Agilent HercepTest™ mAb pharmDxDiagnostic Test: Ventana PD-L1 SP263 assay
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 620
- Registration Number
- NCT06467357
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
Early Phase 1
Recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Biological: RilvegostomigBiological: SabestomigCombination Product: AZD9592 + RilvegostomigCombination Product: AZD9592 + VolrustomigCombination Product: AZD9592 + SabestomigCombination Product: AZD9592 + Pembrolizumab
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Presage Biosciences
- Target Recruit Count
- 15
- Registration Number
- NCT06366451
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸UC Davis, Sacramento, California, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Phase 3
Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 675
- Registration Number
- NCT06357533
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath